Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-001020
Filing Date
2025-02-14
Accepted
2025-02-14 16:06:00
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7285
  Complete submission text file 0000902664-25-001020.txt   9290
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Subject) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88372 | Film No.: 25628403
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 4 EMBARCADERO CENTER SUITE 3450 SAN FRANCISCO CA 94111
Business Address 4 EMBARCADERO CENTER SUITE 3450 SAN FRANCISCO CA 94111 415-801-4550
Woodline Partners LP (Filed by) CIK: 0001784547 (see all company filings)

EIN.: 831749088 | State of Incorp.: DE
Type: SCHEDULE 13G/A